Group sales in 2016

CHF 50.6 bn

+4%*
  • All financial targets for 2016 achieved
  • Good performance in both divisions
  • Very good progress in the product pipeline
  • Among the top 10 investors in R&D across industries

Key financials

Good sales and profit growth in 2016

CHF bn

Group sales

2016
50.6 bn +4%*
2015
48.1 bn

CHF bn

Pharmaceuticals Divison

2016
39.1 bn +3%*
2015
37.3 bn

CHF bn

Diagnostics Division

2016
11.5 bn +7%*
2015
10.8 bn

CHF bn

Core operating profit

2016
18.4 bn +4%*
2015
17.5 bn

CHF bn

IFRS net income

2016
9.7 bn +7%*
2015
9.1 bn

CHF

Core earnings per share

2016
14.53 +5%*
2015
13.49

Business highlights

We have made significant progress in launching new medicines and diagnostic products as well as in advancing our product pipeline.

Watch the video
Watch the video

Redefining treatment in oncology

Cancer immunotherapy Tecentriq available against bladder and lung cancer

Transforming laboratory work

cobas e 801 platform launched for faster and simpler laboratory testing

Recognised for innovation

Five breakthrough therapy designations granted by the US Food and Drug Administration (FDA)

Managing rare blood disorder

Potential new medicine emicizumab significantly reducing number of bleeds in people with haemophilia A

Partnering to improve care

Formal agreements signed with several sub-Saharan countries to improve access to healthcare

Embedding sustainability in our business

Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Indices (DJSI) for the eighth year running

Pharmaceuticals sales

CHF 39.1 bn

+3%*
  • Sales growth mainly driven by cancer medicines Perjeta and Herceptin as well as Actemra/RoActemra
  • Successful launches of four new medicines
  • Five breakthrough therapy designations granted by the US Food and Drug Administration (FDA)
  • Positive late-stage clinical trial results for a new molecule treating haemophilia A

Medicines

Sales of top-selling products in 2016 (CHF millions)

MabThera/Rituxan

Immunology & Oncology

7,300

+3%*

Avastin

Oncology

6,783

0%*

Herceptin

Oncology

6,782

+4%*

Perjeta

Oncology

1,846

+26%*

Actemra/RoActemra

Immunology

1,697

+16%*

Xolair

Immunology

1,498

+15%*

Lucentis

Ophthalmology

1,406

-10%*

Activase/TNKase

Cardiovascular

1,108

+16%*

Tarceva

Oncology

1,024

-15%*

Kadcyla

Oncology

831

+7%*

Diagnostics sales

CHF 11.5 bn

+7%*
  • Sales growth driven primarily by immunodiagnostic solutions
  • Market leader in the laboratory business
  • Introduction of nine key instruments and tests
  • Successful launch of new immunochemistry instrument cobas e 801

Diagnostics products

Sales of top-selling product portfolios in 2016 (CHF millions)

cobas

Immunodiagnostics

3,394

+13%*

Accu-Chek

Diabetes Care

2,016

-4%*

cobas

Clinical chemistry

1,675

+6%*

Ventana

Advanced staining

685

+9%*

cobas

Virology

632

+9%*

Chairman’s voice

Innovation remains our way to create value.

CEO’s voice

Our product pipeline has made very good advances.